Product Overview
Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase (Omicron variant, BQ.1) encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-2 spike protein (T19I, Δ69-70, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K). Because the infectivity of Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices.The pseudotype VSV particles encode Luciferase together with the VSV nucleocapsid (N), phosphoprotein (P), glycoprotein (G), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, Luciferase expression is proportional to the number of cells that were infected.
Alternative Names
SARS-CoV-2; Coronavirus; SARS-CoV; SARS-CoV-2 Spike Protein; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Syndrome-1; Severe Acute Respiratory Syndrome glycoprotein; Severe Acute Respiratory Syndrome-1 glycoprotein; SARS-CoV-2 Pseudovirus; SARS-CoV Pseudovirus; SARS Pseudovirus; SARS-CoV-2 RVP; SARS-CoV-2 Reporter Virus Particle; VSV pseudovirus
COA
Publication 
Loading ......
